Intended for healthcare professionals

Letters Aducanumab for Alzheimer’s disease?

Aducanumab, amyloid, and culture wars

BMJ 2021; 374 doi: https://doi.org/10.1136/bmj.n2038 (Published 19 August 2021) Cite this as: BMJ 2021;374:n2038
  1. Steve Iliffe, emeritus professor of primary care for older people1,
  2. Jill Manthorpe, professor of social work and director2
  1. 1University College London, London, UK
  2. 2Policy Institute, King’s College London, London, UK
  1. s.iliffe{at}ucl.ac.uk

Those who thought that the US Food and Drug Administration (FDA) was a conservative regulator which maintained a high bar have been shocked by its approval of the anti-amyloid antibody aducanumab.

There is precedent. Former president Donald Trump championed hydroxychloroquine as a preventative against covid-19. There were no data to suggest that it worked, but under pressure the FDA gave an emergency use authorisation, only to withdraw …

View Full Text

Log in

Log in through your institution

Subscribe

* For online subscription